BD introduces new safety solution to help prevent IV medication administration errors

BD Showcases Solutions and Technologies to Improve Patient Safety Across the Continuum of Care at #EAHP2017

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medication technology company, announced today the availability of its new IV Medication Safety Solution, designed to help to measurably prevent IV medication administration errors. This announcement was made at the European Association of Hospital Pharmacists (EAHP) congress, being held in Cannes, France March 22-24.

IV medication errors are a serious health care issue. They can occur at any stage of the medication delivery process, from prescription to administration and those occurring at the administration stage are the hardest to intercept. Their impact depends on the route of administration, type of drug and patient characteristics. In particular, intravenous (IV) infusions are identified as frequent contributors to medication errors and patient injuries that result from them. Clinical burden associated with infusion administration errors is suggesting potentially serious consequences for the patient in up to 29 percent of all observed infusions.

BD provides advanced IV medication safety solutions, through helping to standardise drug library protocols with the Alaris™ Editor, to protect the patient with Alaris™ Plus Pumps with Guardrails™ Safety Software, and to evaluate IV medication errors and clinical practice using the Alaris™ CQI Reporter software and clinical services.

To take a step further in patient safety, BD today is launching the Alaris™ Communication Engine Platform, an enterprise IT software platform providing automated centralised management of all connected infusion devices. This system enables remote networked updates to the hospital drug library without interrupting the patient’s infusions, collecting rich and actionable continuous quality improvement (CQI) data and centralising infusion pump device management.

The Alaris™ Communication Engine Platform is a key accelerator to BD’s IV Medication Safety Solution, demonstrating proven results helping to improve medication errors reduction and cost associated to such errors while providing continuous quality improvement.

“As we continue to provide innovative thinking to address the unmet needs in the area of medication management, BD recognises the growing contributions of connectivity,” said Fernand Goldblat, vice president and general manager of Medication Management Solutions Infusion business for BD Europe. “With our IV Medication Safety Solution, BD can assist in creating a safer medication management process for patients while decreasing costs related to preventable adverse events. This addition to our leading Alaris™ technologies portfolio exemplifies our commitment to transform infusion solutions by making them simpler, seamless and connected.”

This latest development, enhances BD’s End-to-End IV Safety capabilities within the Medication Management Solutions portfolio, comprised by the following elements:

  • Medication Management Innovation: Through this unique “one partner” approach, BD is the only company that can offer health systems a holistic approach to manage medications throughout admissions, preparation and dispensing. This approach has the power to simplify and streamline medication management processes across the continuum of care. This further advanced for example, by Rowa™ Dose which allows Hospitals to receive individualised medication’s barcoded pouches both for acute and/or long term patients.
  • Medication Availability: BD technologies help ensure that the right medication is available when and where needed to improve outcomes and cost-efficiency across the continuum of care. By enabling enterprise-wide medication management and analytics for all medications, BD solutions can improve and automate medication orders and delivery, including IVs and controlled substances.
  • End-to-End IV Safety: BD offers clinically proven solutions to help minimise drug management risks while remaining continuously focused on improving and enhancing safety throughout medication management process: from initial compounding to administration at patient’s bedside, including today’s IV Medication Safety Solution announcement.

Where to find BD at EAHP

To learn more about BD’s IV Medication Safety Solution and Medication Management solutions portfolio, including Rowa™ Dose, visit BD booth #81 and participate in our satellite symposium:

  • Shifting the Paradigm: Improving Safety From Pharmacy To Every Point Of Care Symposium March 23, 15:00 – 16:30 Esterel Room

Learn the importance of decreasing preventable errors throughout different stages of the medication management workflow, optimizing efficiency and reducing risk of exposure to hazardous drugs during preparation.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    BD (Becton, Dickinson and Company). (2019, June 18). BD introduces new safety solution to help prevent IV medication administration errors. News-Medical. Retrieved on July 20, 2024 from

  • MLA

    BD (Becton, Dickinson and Company). "BD introduces new safety solution to help prevent IV medication administration errors". News-Medical. 20 July 2024. <>.

  • Chicago

    BD (Becton, Dickinson and Company). "BD introduces new safety solution to help prevent IV medication administration errors". News-Medical. (accessed July 20, 2024).

  • Harvard

    BD (Becton, Dickinson and Company). 2019. BD introduces new safety solution to help prevent IV medication administration errors. News-Medical, viewed 20 July 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
BD launches first automated phenotypic test for CPO detection